Last reviewed · How we verify
CBD oil
CBD oil, marketed by Khon Kaen University, holds a position in the cannabis-derived therapeutic market. The key composition patent expires in 2028, providing a significant period of exclusivity. The primary risk is the lack of clear primary indication and revenue data, which may affect market perception and investment.
At a glance
| Generic name | CBD oil |
|---|---|
| Also known as | Cannabidiol |
| Sponsor | Khon Kaen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy (PHASE1)
- Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden (PHASE2)
- Topical CBD Scar Healing Study (PHASE1)
- Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure (PHASE1)
- Study of Cannabidiol in Sanfilippo Syndrome (PHASE2, PHASE3)
- Evaluation of Oral THC and CBD in Men and Women (PHASE1)
- Cannabidiol and Alcohol Use Disorder Phenotypes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |